Cabaletta Bio (CABA) Competitors $2.90 +0.01 (+0.35%) Closing price 04:00 PM EasternExtended Trading$2.90 0.00 (-0.17%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CABA vs. ANAB, VALN, PHAT, PROK, KURA, AVBP, PVLA, MRVI, CRMD, and ABUSShould you be buying Cabaletta Bio stock or one of its competitors? The main competitors of Cabaletta Bio include AnaptysBio (ANAB), Valneva (VALN), Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Kura Oncology (KURA), ArriVent BioPharma (AVBP), Palvella Therapeutics (PVLA), Maravai LifeSciences (MRVI), CorMedix (CRMD), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Cabaletta Bio vs. Its Competitors AnaptysBio Valneva Phathom Pharmaceuticals ProKidney Kura Oncology ArriVent BioPharma Palvella Therapeutics Maravai LifeSciences CorMedix Arbutus Biopharma AnaptysBio (NASDAQ:ANAB) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Which has stronger valuation and earnings, ANAB or CABA? Cabaletta Bio has lower revenue, but higher earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnaptysBio$91.28M10.52-$145.23M-$4.48-7.65Cabaletta BioN/AN/A-$115.86M-$2.71-1.07 Do analysts recommend ANAB or CABA? AnaptysBio currently has a consensus price target of $54.78, suggesting a potential upside of 59.75%. Cabaletta Bio has a consensus price target of $13.44, suggesting a potential upside of 363.60%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than AnaptysBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AnaptysBio 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.67Cabaletta Bio 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Is ANAB or CABA more profitable? Cabaletta Bio has a net margin of 0.00% compared to AnaptysBio's net margin of -107.66%. Cabaletta Bio's return on equity of -92.11% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets AnaptysBio-107.66% -366.98% -30.58% Cabaletta Bio N/A -92.11%-74.08% Which has more volatility and risk, ANAB or CABA? AnaptysBio has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Does the media prefer ANAB or CABA? In the previous week, AnaptysBio had 1 more articles in the media than Cabaletta Bio. MarketBeat recorded 16 mentions for AnaptysBio and 15 mentions for Cabaletta Bio. AnaptysBio's average media sentiment score of 0.52 beat Cabaletta Bio's score of 0.49 indicating that AnaptysBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AnaptysBio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 1 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCabaletta Bio beats AnaptysBio on 9 of the 13 factors compared between the two stocks. Get Cabaletta Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CABA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CABA vs. The Competition Export to ExcelMetricCabaletta BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$265.23M$3.40B$6.04B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-1.0722.9285.4427.36Price / SalesN/A268.92515.69196.40Price / CashN/A46.9537.5761.53Price / Book0.9310.5512.426.82Net Income-$115.86M-$52.58M$3.32B$276.89M7 Day Performance20.33%1.09%1.01%0.27%1 Month Performance51.83%16.09%10.75%8.31%1 Year Performance-33.03%18.41%76.20%35.60% Cabaletta Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CABACabaletta Bio2.9994 of 5 stars$2.90+0.3%$13.44+363.6%-32.0%$265.23MN/A-1.0750High Trading VolumeANABAnaptysBio2.6382 of 5 stars$32.46+3.5%$52.00+60.2%-8.3%$908.78M$123.16M-7.25100Analyst ForecastVALNValneva2.175 of 5 stars$10.50+1.3%$15.00+42.9%+84.2%$902.27M$183.52M-10.71700PHATPhathom Pharmaceuticals2.3992 of 5 stars$12.53+6.0%$17.50+39.7%-18.2%$888.93M$114.04M-2.65110PROKProKidney2.6524 of 5 stars$2.99-1.0%$6.25+109.0%+76.6%$879.90M$80K-5.253KURAKura Oncology4.012 of 5 stars$9.93+0.8%$24.10+142.7%-46.7%$861.89M$83.28M-4.39130AVBPArriVent BioPharma2.0781 of 5 stars$20.90+0.2%$39.14+87.3%-28.4%$847.91MN/A-5.2040Analyst DowngradePVLAPalvella Therapeutics2.0223 of 5 stars$76.22+9.0%$75.50-0.9%N/A$842.99M$42.81M-6.30N/AMRVIMaravai LifeSciences3.3314 of 5 stars$3.30+3.4%$5.22+58.1%-60.9%$842.70M$219.83M-2.43610Analyst ForecastCRMDCorMedix2.8421 of 5 stars$10.58-1.4%$18.00+70.1%+4.8%$825.88M$43.47M14.1130ABUSArbutus Biopharma1.2616 of 5 stars$4.28+4.1%$5.00+16.8%+9.8%$820.47M$15.42M-14.7690 Related Companies and Tools Related Companies ANAB Competitors VALN Competitors PHAT Competitors PROK Competitors KURA Competitors AVBP Competitors PVLA Competitors MRVI Competitors CRMD Competitors ABUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CABA) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cabaletta Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cabaletta Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
